Genetic variation in toll-like receptor 4 gene with primary antiphospholipid syndrome susceptibility: a cohort of Egyptian patients

Egyptian Journal of Medical Human Genetics

Table 2 Distribution of aPL positivity among healthy controls and patients with PAPS

Group	ANA, n (%)	aCL		anti-β2GPI		LA
Group	ANA, n (%)	IgG, n (%)	IgM, n (%)	IgG, n (%)	IgM, n (%)	aPTT-LA sensitive, n (%)	dRVVT, n (%)
PAPS (65 cases)	0 (0%)	9 (13.8%)	12 (18.5%)	2 (3.1%)	2 (3.1%)	61 (93.8%)	39 (60%)
Control (45 cases)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

Categorical variables are expressed as frequencies (percentage). aPLs antiphospholipid antibodies, PAPS primary antiphospholipid syndrome, aCL anticardiolipin, ANA antinuclear antibody, anti-β2GPI anti-β2 glycoprotein I, dRVVT dilute Russell viper venom time test, LA lupus anticoagulant, aPTT-LA sensitive activated partial thromboplastin time lupus anticoagulant sensitive